The efficacy of T-DXd for advanced or metastatic HER2-positive breast cancer after progression on T-DM1 was established in the DESTINY-Breast01 trial [8] and confirmed in the randomised phase 3 DESTINY-Breast02 [9] trial. The gene discussed is ERBB2; the disease is breast carcinoma.